Open access · US-GOV via ClinicalTrials.gov Clinical trial

A Randomized, Double-blind, Placebo Controlled, Cross-over Clinical Trial of Acute Safety and Biological Effects of a Polyphenol Supplement

Authors not listed

Helse Stavanger HF · 2023

Dysbiosis Human Randomized controlled trial

Abstract

A randomized, double-blind, placebo controlled, cross-over trial to investigate the effect of the Investigational Product "DailyColors™" (DC) on age-related pathways in adults. The aim of this study is to measure the effects of acute treatment with DC on key pathways relevant to healthy ageing using blood biomarkers. Based on power calculations a sample size of 20, is sufficient to detect an effect size of 0.46 at a power \> 90%. To account for dropout the investigators will include 26 subjects in total.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source: ClinicalTrials.gov
Canonical: link ↗
Fetched: 2026-07-02 MST

Cite this

APA

Anonymous. (2023). A Randomized, Double-blind, Placebo Controlled, Cross-over Clinical Trial of Acute Safety and Biological Effects of a Polyphenol Supplement. <em>Helse Stavanger HF</em>. https://clinicaltrials.gov/study/NCT05829382

Vancouver

Anonymous. A Randomized, Double-blind, Placebo Controlled, Cross-over Clinical Trial of Acute Safety and Biological Effects of a Polyphenol Supplement. Helse Stavanger HF. 2023.

BibTeX

@misc{anon2023ARando, title = {A Randomized, Double-blind, Placebo Controlled, Cross-over Clinical Trial of Acute Safety and Biological Effects of a Polyphenol Supplement}, author = {Anonymous}, journal = {Helse Stavanger HF}, year = {2023}, }